C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $6.64 million versus the consensus estimate of $8.2 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.